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ABSTRACT
Arthralgias and spondyloarthropathies of the peripheral and
axial joints are common in inflammatory bowel disease. Evidence
for a strong association between these clinical manifestations and
diseases of the joints has been provided by several clinical and epi-
demiological studies. Immunological studies have shown the pres-
ence of shared inflammatory cells both in the gut and the synovi-
um in spondyloarthropathies. Genetic factors play a crucial role in
the pathogenesis of spondyloarthropathies and inflammatory
bowel disease. The role of the ubiquitous bacterial flora and path-
ogenic microorganisms present in the intestinal lumen may induce
these joint diseases in patients with inflammatory bowel disease.
In this review we will focus on the pathogenesis of spondy-
loarthropathies and arthralgia in patients suffering from inflamma-
tory bowel disease. Based on preliminary clinical observations in
patients with arthralgia and IBD, we put forward the hypothesis
that probiotics may be helpful in the management of common ex-
traintestinal manifestations such as arthralgia in patients with ul-
cerative colitis and Crohn’s disease.
Key words: Arthralgias. Spondyloarthropathies. Inflammatory
bowel disease. Crohn’s disease.
INTRODUCTION
Seronegative spondyloarthritides, a subgroup of spondy-
loarthropathies (SpA), enclose a group of arthropathies
characterized by the consistent absence of the rheumatoid
factor, the involvement of sacro-iliac joints and the involve-
ment of peripheral inflammatory arthritis. These SpA are
also known as non-erosive, non-deforming arthropathies
(1). This group is clinically distinguishable from the group
of patients with seropositive rheumatoid arthritis. The
prevalence of SpA was shown to be higher in Crohn’s
disease (CD) than in ulcerative colitis (UC) (2). Im-
munopathological studies, such as increased E-cadherin/
catenin complex expression has been observed in clinically
overt IBD and in the subclinically inflamed bowel mucosa
from spondyloarthropathy (SpA) patients (3,4). 
SpA is associated with the histocompatibility antigen
HLA-B27. This marker and other yet unknown genetic
and environmental factors explain the often observed
familial aggregation of SpA and IBD (5-7). Involve-
ment of the gastrointestinal tract is a feature of SpA (8).
Subclinical inflammatory lesions of the gut can evolve
to clinically overt CD. These lesions are found in 25-
75% of SpA patients (9). Clinical articular manifesta-
tions compatible with SpA are shown by 39% of pa-
tients with IBD (7). A research group in Oxford showed
that enteropathic peripheral arthropathy without axial
involvement can be subdivided into a pauciarticular
large joint arthropathy and a bilateral symmetrical poly-
arthropathy. Both subgroups can be distinguished by the
different distribution of joint involvement and the natur-
al history of the disease. Patients with recorded joint
swelling or effusion were classified as type 1 (pauciar-
ticular) when less than five joints were involved, and
classified as type 2 (polyarticular) when five or more
joints were swollen. Patients with joint pain but no evi-
dence of swelling in the joints were classified as suffer-
ing from arthralgia (10).
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THE GUT AND THE JOINT
Gastrointestinal infections associated with SpA usual-
ly involve the terminal ileum and sometimes also the
colon, in most cases without joint symptoms (11,12).
Generally two types of inflammation exist; an acute in-
flammation resembling enterocolitis and a chronic in-
flammation resembling CD. 
The involvement of the genetic marker HLA-B27 may
explain the pathogenesis of joint inflammation. The
HLA-B27 marker is an HLA class-I molecule that binds
microbial antigenic peptides known as arthritogenic pep-
tides. HLA-B27 presents these peptides to CD8+ cytotox-
ic T-cells in the synovium, thus inducing inflammation.
Bacteria that are present in the intestinal lumen of IBD
patients may share epitopes with HLA-B27 antigens. Re-
cently, IBD-specific autoantibodies were found in pa-
tients with HLA-B27-associated SpA (13). According to
Orchard et al. pauciarticular arthropathy (type 1) is clini-
cally and immunogenetically similar to the manifesta-
tions of SpA. According to these authors, different HLA
associations may define phenotypically distinct sub-
groups. In type 1:  HLA-DRB1*0103 in 33% (relative
risk (RR) = 12.1), B*35 in 30% (RR = 2.2), and B*27 in
26% (RR = 4.0). In type 2, i.e., polyarticular arthropathy:
HLA-B*44 in 62% (RR, 2.1)(14). In IBD and SpA there
is a polygenic predisposition and a high prevalence of in-
creased intestinal permeability (15-18). This may suggest
a common etiopathogenesis for arthralgia and SpA in
IBD. Endoscopy and the histology of ileal biopsy speci-
mens have shown a high prevalence of asymptomatic in-
testinal inflammation in patients with assumed idiopathic
ankylosing spondylitis (chronic SpA) with or without the
HLA-B27 marker (19-21). 
The role of increased intestinal permeability was con-
firmed by abdominal scintigraphy with technetium-99m
hexamethylpropylene amine oxime in SpA patients (22).
Colonoscopy showed a statistically significant concor-
dance with abdominal scintigraphy (23).
Immunohistochemical studies in mucosal biopsy
specimens of SpA patients showed an increase in im-
munoglobulin-containing cells, similar to CD and UC
(24). Among immune alterations, an increased number
of the macrophage scavenger receptor CD163 was
found in the synovium and colonic mucosa of SpA pa-
tients (25-27). Several studies have suggested a link be-
tween Gram-negative enterobacteria and IBD (21,28).
The involvement of Yersinia and Salmonella in reactive
arthritis, as well as Shigella, Campylobacter spp. and
Klebsiela, was reported (28,29). The observations by
Orchard and Jewell are consistent with the hypothesis
that luminal bacteria in this region are important in the
pathogenesis of reactive arthritis. They compared a
group of CD patients with ileocecal resection to a group
of CD patients without ileocecal resection. Patients who
underwent ileocecal resection had less arthritic compli-
cations (30). 
NOT ALL PROBIOTICS ARE ALIKE;
COMPARATIVE STUDIES ARE NECESSARY
In order to understand the mechanisms of action of
probiotics, two different concepts have been approached
–one based on the effects of one single strain used as a
food supplement (e.g., Lactobacillus GG and L. casei
Shirota), the other derived from observations made using
a mixture of Lactobacilli, bifidobacteria, and streptococ-
cus (VSL#3) in patients with IBD and arthralgia (31).
With the exception of a recently published study (32), no
comparative studies of different strains or mixtures are
available to date. The choice for one particular strain is
empiric, and a careful recording of their effects is neces-
sary. In the only comparative study that has been pub-
lished, two different strains (Lactobacillus salivarius and
Bifidobacterium infantis) were compared in patients with
irritable bowel syndrome. Bifidobacterium infantis was
found to normalize the antiinflammatory-to-proinflam-
matory cytokines ratio, whereas no changes in the cy-
tokine profiles were induced by L. salivarius and place-
bo. More comparative studies are needed to find the
superiority of each specific strain for a specific symptom
(32,33).
PROBIOTICS IN POUCHITIS AND IBD
Probiotics are live microbial feed supplements that
benefit the host by improving intestinal microbial bal-
ance, and that probably induce benefits in health that nor-
mal nutrition is not able to achieve (34). The lumen of the
intestine contains bacteria, bacterial products, and dietary
antigens capable of initiating and sustaining inflamma-
tion. Although the mechanisms of action of probiotics are
still unclear, their beneficial effects on the improvement
of intestinal microbial balance have already been de-
scribed for decades (35).
Evidence for a therapeutic role of probiotics in the re-
mission and prevention of patients with pouchitis, a non-
specific ileal inflammation occurring in the ileal reservoir
after proctocolectomy for UC, was provided by Gionchetti
et al. (36). 
PROBIOTICS IN THE MANAGEMENT OF
ARTHRALGIA IN PATIENTS WITH IBD
To study the safety and efficacy of probiotics in pa-
tients with quiescent IBD who suffered from arthralgia
for more than two weeks, Karimi et al. administered oral
probiotics (VSL#3) to these patients. Preliminary results
suggested that this probiotic mixture may be an alterna-
tive treatment for arthralgia in some patients with IBD,
without inducing exacerbation of inflammatory bowel
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disease as NSAIDs do (37,38).
OBSERVATIONS AND RATIONALE
SUPPORTING AN INDICATION FOR
PROBIOTICS IN ARTHRALGIA AND SpA IN
PATIENTS WITH IBD
The beneficial effects of Lactobacillus GG both in the
prevention and treatment of T-cell-dependent experimen-
tal arthritis were also demonstrated in two animal models
suggesting a beneficial effect of the use of probiotics in
experimental arthropathy (39). 
BASIC MECHANISMS 
The modulation of COX2 expression is an important
mechanism of the anti-inflammatory and anticarcino-
genic property of some probiotics (40). The probiotic
Lactobacillus rhamnosus GG was found to induce COX2
expression in human T84 colon epithelial cells (41). The
importance of COX2-dependent arachidonic acid
metabolites as immunoregulatory molecules in the in-
testinal mucosa is emphasized by the observation that
NSAIDs, often efficacious in the treatment of arthropa-
thy, may induce a flare-up of IBD (42-44). COX2-depen-
dent arachidonic acid metabolites are essential in the de-
velopment and maintenance of intestinal immune
homeostasis (45). 
Recently, a mitogen-activated protein kinase (MAPK)
called p38 has been reported as a mediator of endotoxin-
induced production of COX2 in enterocytes (46). The in-
hibition of the p38 MAPK pathway may inhibit COX2
expression. This is relevant because previous studies
have shown that probiotic bacteria inhibit the p38 MAPK
pathway (47). We therefore hypothesize that the link be-
tween p38 and COX2 may explain the beneficial effect of
probiotics in the treatment of arthralgia since probiotic
bacteria inhibit this pathway and have a role in prevent-
ing intestinal cancer.
INFLIXIMAB (ANTI-TNF-α), NF-κB AND
PROBIOTICS IN PATIENTS WITH ANKYLOSING
SPONDYLITIS, IBD, AND SpA, AND IN
EXPERIMENTAL ANIMAL MODELS OF
COLITIS
The efficacy and safety of infliximab in patients with
ankylosing spondylitis has been tested in a randomized,
placebo-controlled trial showing that infliximab was well
tolerated and effective in a large cohort of patients with
ankylosing spondylitis during a 24-week study period
(48). Patients with Crohn’s disease and SpA have also
been effectively treated with infliximab, a tumor necrosis
factor alpha (TNF-α) blockade (49,50). In an experimen-
tal study, the administration of VSL#3 to IL-10 deficient
mice showed a reduction of microscopic infection togeth-
er with a reduction in the mucosal secretion of TNF-α
and IFN-γ (51). These studies may suggest that probiotics
may facilitate an anti-inflammatory effect of TNF-α
blockade. Probiotic VSL#3 appears to reduce the inflam-
mation of the gut mucosa by blocking NF-κB activity
and to increase cytoprotection through heat shock protein
induction, mediated by inhibition of the proteasome (52). 
INTESTINAL PERMEABILITY, IL-10 AND
PROBIOTICS IN PATIENTS WITH IBD AND IN
EXPERIMENTAL ANIMAL MODELS OF
COLITIS
Treatment with the probiotic VSL#3 has demonstrated
a reduction of colonic permeability in both IL-10 gene-
deficient mice and control mice. This may suggest that
the type and quantity of bacterial species in the colon
modulate intestinal permeability (53-55). Furthermore,
Ulisse et al. have shown that VSL#3 probiotics induce a
significant increase in the expression of the anti-inflam-
matory cytokine IL-10 in the mucosal reservoir of pa-
tients with pouchitis compared to similar patients treated
with antibiotics (56). The administration of VSL#3 probi-
otic has been studied in a Th1 T-cell colitis, which was
induced by trinitrobenzene sulfonic acid treatment in
SJL/J mice. Daily administration of VSL#3 to these mice
for a period of 3 weeks, during a remission period be-
tween a first and second course of trinitrobenzene sulfon-
ic acid, resulted in a milder form of recurrent colitis than
observed in mice administered PBS during this same pe-
riod. This outcome was due to the induction of an im-
munoregulatory response involving TGF-β-bearing regu-
latory cells since anti-IL-10R or anti-TGF-β abolished
the beneficial effects of the probiotic mixture (57). 
Although the safety of probiotics containing lacto-
bacilli and bifidobacteria has been evaluated critically,
and probiotics were considered to be at least as safe as
appropriate traditional reference food (58), one has to
take into consideration that not all probiotic bacteria have
similar therapeutic effects as stated earlier. 
The terminal ileum, and in particular the increased
permeability of the terminal ileum, play a key role in the
link between intestinal inflammation and SpA. It seems
that the most important effect of probiotics in ameliorat-
ing arthralgia in patients with IBD and SpA is the en-
hancement of the intestinal barrier. This hypothesis is
supported by experimental observations in mice de-
scribed by Madsen et al. (59). Isolauri et al. (55) de-
scribed that prolonged cow milk challenge in suckling
rats increases gut permeability to intact proteins, whereas
Lactobacillus GG counteracts this permeability disorder.
CONCLUSION
Based on the results of experimental animal models,
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the concepts described in this review and our preliminary
clinical observations, we believe that the use of probi-
otics may be effective in the management of patients with
IBD suffering from arthralgia and/or SpA. Controlled
randomized clinical trials to investigate the unresolved
issues related to efficacy, dose, and duration of use, sin-
gle or multi-strain formulation, are necessary to prove the
beneficial effect of probiotics in patients with IBD,
arthralgia and/or SpA. 
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